PCA 50941, a novel Ca2+ channel agonist

Area of Science:

• Pharmacology
• Cardiovascular Research
• Medicinal Chemistry

Background:

• 1,4-dihydropyridine derivatives are crucial in cardiovascular research.
• Calcium channel activators like Bay K 8644 have known cardiovascular effects.
• Understanding novel derivatives' profiles is essential for therapeutic development.

Purpose of the Study:

• To systematically compare the cardiovascular effects of PCA 50941 with the prototypic Ca2+ channel activator, Bay K 8644.
• To investigate the tissue selectivity and mechanism of action of PCA 50941.
• To evaluate PCA 50941's potential as a cardiovascular agent.

Main Methods:

• Comparative analysis of vasoconstricting and inotropic effects in isolated tissues (guinea-pig atria, rat heart, rat aorta, portal vein, pig coronary arteries).
• Assessment of coronary flow in isolated perfused rat heart.
• Evaluation of dose-dependent responses to Ca2+ and compounds.

Main Results:

• PCA 50941 demonstrated pronounced vascular selectivity over cardiac effects, unlike Bay K 8644.
• PCA 50941 exhibited negative inotropic effects in the rat heart and weak/negative effects in guinea-pig atria.
• PCA 50941 showed biphasic vasoconstriction/vasorelaxation in rat aorta and reduced Ca2+-evoked contractions in portal vein, contrasting with Bay K 8644's pure vasoconstriction.

Conclusions:

• PCA 50941 acts as a selective Ca2+ channel modulator with both agonistic and antagonistic properties on 1,4-dihydropyridine receptors.
• Its favorable tissue selectivity and prolonged action suggest a superior cardiovascular profile compared to existing Ca2+ agonists.
• PCA 50941 warrants further investigation for potential therapeutic applications in cardiovascular diseases.